Helix Selects DNA Genotek’s Oragene® Collection Device and GenoFIND Fulfillment Services for Genetic Discovery Application...
2016年11月29日 - 8:00PM
- Oragene®●Dx saliva
collection kits to provide reliable DNA samples for Helix -
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care
diagnostic tests and specimen collection devices, announced today
that Helix, the personal genomics company, has selected the
Oragene
®●Dx device to provide reliable
self-collection of DNA samples to be used in a genetic information
discovery service offered by Helix for consumers. OraSure’s
wholly-owned subsidiary, DNA Genotek, will supply the
Oragene
®●Dx device and will also provide kit
fulfillment and logistics services for Helix through its GenoFIND
offering.
Helix provides a secure and affordable means for consumers to
access data and information about their DNA, through uniquely
personalized applications created by Helix partners. The
Oragene®●Dx collector will be used to collect
saliva samples from consumers and those samples will be sequenced
in Helix’s lab. Customers will then be able to access DNA-powered
insights in products and experiences created by Helix
partners—including well-known clinical and consumer brands—in the
areas of health, fitness, genealogy, family planning, lifestyle,
and nutrition.
“Reliable and easy-to-use sample collection is a key part of our
offering. The ability to collect a high quality DNA sample for next
generation sequencing is critical to ensuring accurate results for
our customers,” said Dr. James Lu, Co-founder & Senior Vice
President of Applied Genomics at Helix. “DNA Genotek is a leader in
its field, and we are excited to work with them to bring customers
an efficient experience right from the start.”
"We are pleased that Helix has selected both our saliva
collection kits and GenoFIND services to support their offering.
Their vision and approach to empowering every person to improve
their life through DNA is truly innovative and we are excited that
Oragene®●Dx will be an integral part of the Helix
customer experience,” said Brian Smith, Senior Vice President and
General Manager at DNA Genotek.
Oragene®●Dx is an all-in-one system for the
easy self-collection and stabilization of DNA from saliva. The
device allows for ambient temperature storage and transportation
and provides a liquid sample to enable high throughput automated
processing in a laboratory. Oragene®●Dx is the
first and only DNA collection and stabilization device to receive
510(k) clearance in the USA. GenoFIND offers a complete suite of
genomics and microbiome services from study design through
bioinformatics analysis and interpretation.
Oragene®●Dx is FDA 510(k) cleared for in vitro
diagnostic use with the eSensor® Warfarin Sensitivity Saliva
Test.
About DNA Genotek
DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc.
(NASDAQ:OSUR), focuses on providing high-quality biological sample
collection products and end-to-end services for human genomics,
microbiome and infectious disease applications. The Company's
Oragene®•Dx and ORAcollect®•Dx
product lines are the first and only FDA 510(k) cleared
saliva-based DNA collection devices for in vitro diagnostic use.
DNA Genotek also offers Research Use Only products to collect and
preserve large amounts of DNA or RNA from multiple sample types.
DNA Genotek markets its products worldwide and has a global
customer base with thousands of customers in over 100 countries.
For more information about DNA Genotek, visit
www.dnagenotek.com.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of point of care diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its first-to-market, innovative products
include rapid tests for the detection of antibodies to HIV and HCV
on the OraQuick® platform, oral fluid sample collection,
stabilization and preparation products for molecular diagnostic
applications, and oral fluid laboratory tests for detecting various
drugs of abuse. OraSure's portfolio of products is sold globally to
various clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, research and
academic institutions, distributors, government agencies,
physicians' offices, commercial and industrial entities and
consumers. The Company's products enable healthcare providers to
deliver critical information to patients, empowering them to make
decisions to improve and protect their health. For more
information on OraSure Technologies, please visit
www.orasure.com.
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
Ron Ticho
SVP, Corporate Communications
484-353-1575
media@orasure.com
OraSure Technologies (NASDAQ:OSUR)
過去 株価チャート
から 6 2024 まで 7 2024
OraSure Technologies (NASDAQ:OSUR)
過去 株価チャート
から 7 2023 まで 7 2024